Drugs / VUM02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06677255 | Jan 2025 → Dec 2026 expected | acute graft versus host disease | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VUM02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06677255 ↗ |
| Modality | Cell therapy | “VUM02 Injection (human umbilical cord-derived mesenchymal stromal /stem cells, hUC-MSC) is an off-the-shelf allogeneic cell therapy product” NCT06677255 ↗ |
| Route | Intravenous | “a single intravenous infusion of VUM02 Injection” NCT06677255 ↗ |